Addendum
Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06
Report documents
-
Addendum
Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06
Dossier assessment
Indication:
Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)
Result of dossier assessment:
Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: added benefit not proven. PPMS: indication of lesser benefit than appropriate comparator therapy
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-38
- Commission
- Commission awarded on 12.06.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed